The most recent Form 13F filing that Truist Financial Corp. made with the Securities and Exchange Commission revealed that the company’s holdings in Catalent, Inc. (NYSE: CTLT) were reduced by 8.7% during the third quarter. The company provided this information. The institutional investor had 67,666 shares of the company’s stock at the end, which they obtained after selling 6,468 shares of its stock throughout the time frame. At the end of the most recent financial quarter, it was determined that the value of Truist Financial Corporation’s Catalent holdings was $4,896,000. This was the most recent valuation.
As a further consequence of these modifications, the total number of shares of stock that institutional investors and other hedge funds collectively own in the company has also been modified accordingly. FDx Advisors Inc. increased the amount of Catalent stock owned by 1.9% over the second quarter. During the most recent fiscal quarter, FDx Advisors Inc. increased its stake in the company by purchasing 108 additional shares, bringing the total number of shares it currently owns to 108, with a market value of $613,000. During the second quarter, Quadrant Capital Group LLC successfully elevated the percentage of Catalent shares it owned to 8.9%. During the most recent fiscal quarter, Quadrant Capital Group LLC successfully acquired an additional 115 shares of the company’s stock, bringing the total number of shares owned directly by the company to 1,411. The total value of these shares comes to $151,000. During the first three months of 2018, Cetera Advisor Networks LLC acquired an additional 7.1% worth of shares in Catalent. Cetera Advisor Networks LLC now has a total of 1,953 shares in the company, which have a value of $217,000 due to the purchase of an additional 130 shares during the most recent fiscal period. Mackay Shields LLC added 0.6% more Catalent stock to its holdings over the first three months of 2018. Mackay Shields LLC now directly owns 25,749 shares of the company’s stock, which have a value of $2,856,000 after purchasing an additional 149 shares of the company’s stock during the most recent fiscal quarter. This brings the total number of shares directly owned by the company to 25,749; last but not least, during the second quarter, Colony Group LLC added 0.4% more Catalent stock to its holdings, bringing the total to a percentage that was 0.6% higher. The most recent fiscal quarter saw Colony Group LLC acquire 172 additional shares, bringing the total number of shares directly owned by the company to 45,671, with a value of $4,900,000. The vast majority of the company’s shares, or 99.38%, are owned by various institutional investors such as hedge funds and other investment companies.
During the previous calendar year, the share price of Catalent, Inc., has moved in a range that has taken it from a low of $40.69 to a high of $115.36, and trading began for the day on Friday at $49.35. The share price-to-earnings ratio is 21.09, the price-to-earnings growth ratio is 3.29, and the stock’s beta value is 1.24. The stock’s market capitalization is $8.88 billion. The company’s simple moving average over the past 50 days is $45.44, and the simple moving average over the past 200 days is $75.82. There is a debt-to-equity ratio that is equal to 0.87, a current ratio that is equal to 2.86, a quick ratio that is equal to 2.08, and a current ratio that is equal to 2.86.
The most recent quarterly earnings report for Catalent, traded on the New York Stock Exchange under the symbol CTLT, was released on November 1. The company reported quarterly earnings of $0.25 per share, which was $0.24 less than the average expectation of $0.49 per share held by industry experts. The company also reported a net income of $0.00 for the quarter. Catalent achieved a return on equity of 12.55%, and the net margin for the company was 8.83%. Despite predictions made by analysts that the company would bring in $1.06 billion during the quarter, the actual revenue that the company was able to bring in was only $1.02 billion. According to the consensus of industry experts, Catalent, Inc. will bring in profits of $2.93 per share during the current financial year.
On Monday, December 5, an employee of the company who is considered an insider, Manja Boerman, sold 780 shares of the company’s stock. This is another development on this topic. It was determined that the shares were sold at an average price of $51.70 each, which led to a total sale volume of $40,326.00. This price was determined based on the findings of the investigation. The company insider now has 15,860 shares of the company, which are worth a total of $819,962 thanks to the purchase that was made. The Securities and Exchange Commission was given legal documents about the transaction, which were subsequently uploaded to the SEC website after being provided to the SEC. On Monday, December 5, an employee of the company who is considered an insider, Manja Boerman, sold 780 shares of the company’s stock. This is another development on this topic. It was determined that the shares were sold at an average price of $51.70 each, which led to a total sale volume of $40,326.00. This price was determined based on the findings of the investigation.
The company insider now has 15,860 shares of the company, which are worth a total of $819,962 thanks to the purchase that was made. The Securities and Exchange Commission was given legal documents about the transaction, which were subsequently uploaded to the SEC website after being provided to the SEC. Additionally, on Monday, October 31, Senior Vice President Michael J. Grippo sold 2,451 shares of company stock. The shares were acquired for a total cost of $161,349.33, which works out to a price of $65.83 per share on an average basis. As a result of the completion of the transaction, the senior vice president now directly owns 17,792 shares of the company’s stock. Based on the current stock price, these shares are estimated to be worth approximately $1,171,247.36. Disclosures that are related to the sale might be found in this section of the website. The company’s insiders own 0.58 percent of the total number of shares outstanding.
Recent months have seen the release of several research reports concerning CTLT. Robert W. Baird lowered their price objective on Catalent shares from $123.00 to $75.00 in a research note published on November 2. In a research note published on November 2, Barclays downgraded Catalent from an “overweight” rating to a “neutral” one. Additionally, they decreased their price objective on the stock from $105.00 to $62.00. Both of these adjustments were made as a direct result of recent occurrences in the market. In a research note published on November 3, Morgan Stanley gave Catalent an “underweight” rating, down from the previous rating of “overweight.” In addition, Morgan Stanley dropped their price objective for the stock from $120.00 to $81.00, bringing it closer to the current market price. In a research note by KeyCorp on November 2, the company announced that it had lowered its rating for Catalent from “overweight” to “neutral.” In addition, the price target for Catalent shares dropped from $125.00 to $85.00, reflecting the reduction in the price target. Finally, TheStreet decreased its rating on Catalent shares from “b-” to “c+” in a research note published on Friday, October 28. This change reflects a lower overall level of confidence in the company. Four research analysts have given the company a recommendation to buy their stock, three research analysts have recommended that the company’s stock be held, and one research analyst has recommended that the company’s stock be sold. According to information compiled by Bloomberg, the current rating for Catalent’s stock is “Hold,” and the average price target for the company’s shares is $92.80. This information was derived from the opinions of analysts covering the company.
Research and manufacturing solutions for the pharmaceutical industry, the biologics industry based on proteins, the cell and gene therapy industry, and the consumer health goods industry are all areas of focus for Catalent, Inc. and its affiliated companies, which conduct their operations all over the world. The Softgel and Oral Technologies section offers formulation, development, and production services for soft capsules for a wide variety of client products, including prescription drugs, over-the-counter medicines, dietary supplements, unit-dose cosmetics, and animal health medical preparations. These services are provided for soft capsules used in softgels and oral technologies. These services are adaptable enough to work with a wide range of client products.
Source: news.google.com
